Anita Busquets is a highly experienced, start-up executive. Prior to BioTMC, she served as Chief Financial and Administrative Officer of Salmedix, Inc. in San Diego, CA, served as President of NCE Pharmaceuticals and co-founded and served as President of GeneTex, Inc., both San Antonio-based biotechnology firms. Earlier she was employed in positions of increasing responsibility, including Chief Operating Officer, at the CTRC Research Foundation, in San Antonio, and as Director of Finance and Administration, Corvas International, Inc. Earlier in her career, she worked as an auditor with Coopers & Lybrand. Ms. Busquets received her B.S. in Nutritional Sciences from Cornell University and her M.B.A from Simmons Graduate School of Management.
Dr. Richard Lumpkin has 25 years of experience in early stage biotechnology companies. Previous to BioTMC, he was a Sr. Director at Global Blood Therapeutics becoming the first employee of this Third Rock Ventures founded company. He was an original member of the team that spun off Portola Pharmaceuticals from Millennium Pharmaceuticals. Earlier in his career he held positions of increasing responsibility as a synthetic chemist and computer programmer at COR Therapeutics, Amylin and Corvas International, Inc. He received his BS in Geology and Ph.D. in Biochemistry from the University of Missouri – Columbia.
Anita Busquets is a highly experienced, start-up executive. Prior to BioTMC, she served as Chief Financial and Administrative Officer of Salmedix, Inc. in San Diego, CA, served as President of NCE Pharmaceuticals and co-founded and served as President of GeneTex, Inc., both San Antonio-based biotechnology firms. Earlier she was employed in positions of increasing responsibility, including Chief Operating Officer, at the CTRC Research Foundation, in San Antonio, and as Director of Finance and Administration, Corvas International, Inc. Earlier in her career, she worked as an auditor with Coopers & Lybrand. Ms. Busquets received her B.S. in Nutritional Sciences from Cornell University and her M.B.A from Simmons Graduate School of Management.
Dr. Richard Lumpkin has 25 years of experience in early stage biotechnology companies. Previous to BioTMC, he was a Sr. Director at Global Blood Therapeutics becoming the first employee of this Third Rock Ventures founded company. He was an original member of the team that spun off Portola Pharmaceuticals from Millennium Pharmaceuticals. Earlier in his career he held positions of increasing responsibility as a synthetic chemist and computer programmer at COR Therapeutics, Amylin and Corvas International, Inc. He received his BS in Geology and Ph.D. in Biochemistry from the University of Missouri – Columbia.
We met in 1988 as we were part of the original Team assembled by John Crawford and Tom Edgington to get Corvas International off the ground, and that we did.
Over the years we have stayed in touch and worked on a number of projects together, including Epitait, InPhasol and Epitracker/Seraphina Therapeutics. In 2016, we decided to formalize our partnership and formed Biotechnology Management Consultants, BioTMC, for short.
We met in 1988 as we were part of the original Team assembled by John Crawford and Tom Edgington to get Corvas International off the ground, and that we did.
Over the years we have stayed in touch and worked on a number of projects together, including Epitait, InPhasol and Epitracker/Seraphina Therapeutics. In 2016, we decided to formalize our partnership and formed Biotechnology Management Consultants, BioTMC, for short.
We strive to help scientists bring their ideas to fruition by assisting them in creating business plans, forming a company, planning a preclinical and clinical strategy and assisting to raise the funds needed for their success.
We strive to help scientists bring their ideas to fruition by assisting them in creating business plans, forming a company, planning a preclinical and clinical strategy and assisting to raise the funds needed for their success.